Viewing nowCombinationSamsitaplus Tablet 50/850 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.

MFDS item code 202108202 · Approved 2021.12.30 · Insurance code 642308590
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. It is used when patients who have not previously received diabetes medication find it difficult to control their blood sugar with monotherapy. Additionally, this medication is prescribed when there is insufficient glycemic control with monotherapy of metformin or sitagliptin, or to replace the combination therapy of the two drugs. It can also be administered in combination with sulfonylurea, thiazolidinedione, or insulin when glycemic control remains difficult with the combination of metformin and those agents. It serves as an effective therapeutic agent to assist in the management of patients' blood sugar in various circumstances.
The dose of this medication for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medication should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients who have not previously received pharmacologic treatment for diabetes and whose blood glucose is not adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Patients Who Must Not Receive This Medication). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient’s current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medication may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take into account the patient’s blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medication is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral glucose-lowering agents to this medication. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used, with the following dose adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Receive This Medication).
This medication is used in the treatment of diabetes and contains sitagliptin and metformin. When taking this medication, severe allergic reactions may occur, so if symptoms such as skin rash or difficulty in breathing appear, stop taking it immediately and consult a doctor. Additionally, symptoms of acute pancreatitis may occur, so if abdominal pain, nausea, or vomiting occurs, inform the healthcare provider immediately. This medication should not be administered to patients with severely impaired kidney function, severe infections or dehydration, acute heart failure, or women who are pregnant or breastfeeding. Particularly, this medication should be discontinued before tests using iodine contrast agents, and should not be resumed until kidney function is confirmed to be normal after the test. This medication may cause hypoglycemia, so caution is advised when meal intake is irregular or physical activity drastically increases. The risk of hypoglycemia may increase when taken with insulin or sulfonylureas. During treatment, regular monitoring of kidney function and blood tests should be conducted for any abnormalities, and vitamin B12 levels may decrease, so supplementation may be necessary if required. Alcohol may increase the risk of side effects related to this medication, so it is advisable to avoid drinking alcohol during treatment. In case of surgery or severe trauma, this medication should be temporarily discontinued, and it can be resumed after confirming that the patient is capable of oral intake and their kidney function is normal. This medication poses a higher risk of kidney function decline in elderly patients, thus dose adjustments and regular monitoring are necessary. In the event of an overdose, notify healthcare personnel immediately, and treatment such as hemodialysis may be necessary. Any abnormal symptoms or discomfort during treatment should be discussed with a doctor or pharmacist.
Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, severe and disability-associated arthralgia, vesiculobullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, dermatitis, loss of appetite, weight loss, dyspnea, unstable angina, dizziness, acute kidney failure, reduced appetite, gastrointestinal disturbance, itching
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly closed container, protecting it from air, and keep it at room temperature between 1 to 30 degrees Celsius. This helps maintain the effectiveness of the medication for a longer duration.
Pink oval film-coated tablet
30 tablets/box [(10 tablets/PTP×3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.